EVITA: a tool for the early EValuation of pharmaceutical Innovations with regard to Therapeutic Advantage by Püntmann, Isabel et al.
RESEARCH ARTICLE Open Access
EVITA: a tool for the early EValuation of
pharmaceutical Innovations with regard to
Therapeutic Advantage
Isabel Püntmann
1, Norbert Schmacke
2, Arne Melander
3, Gunnar Lindberg
3, Bernd Mühlbauer
1*
Abstract
Background: New drugs are generally claimed to represent a therapeutic innovation. However, scientific evidence
of a substantial clinical advantage is often lacking. This may be the result of using inadequate control groups or
surrogate outcomes only in the clinical trials. In view of this, EVITA was developed as a user-friendly transparent
tool for the early evaluation of the additional therapeutic value of a new drug.
Methods: EVITA does not evaluate a new compound per se but in an approved indication in comparison with
existing therapeutic strategies. Placebo as a comparator is accepted only in the absence of an established therapy
or if employed in an add-on strategy on top. The evaluation attributes rating points to the drug in question, taking
into consideration both therapeutic benefit and risk profile. The compound scores positive points for superiority in
efficiency and/or adverse effects as demonstrated in randomized controlled trials (RCTs), whilst negative points are
awarded for inferiority and/or an unfavorable risk profile. The evaluation follows an algorithm considering the
clinical relevance of the outcomes, the strength of the therapeutic effect and the number of RCTs performed.
Categories for therapeutic aim and disease severity, although essential parts of the EVITA assessment, are attributed
but do not influence the EVITA score which is presented as a color-coded bar graph. In case the available data
were unsuitable for an EVITA calculation, a traffic-type yield sign is assigned instead to criticize such practice. The
results are presented online http://www.evita-report.de together with all RCTs considered as well as the reasons for
excluding a given RCT from the evaluation. This allows for immediate revision in response to justified criticism and
simplifies the inclusion of new data.
Results: As examples, four compounds which received approval within the last years were evaluated for one of
their clinical indications: lenalidomide, pioglitazone, bupropion and zoledronic acid. Only the first achieved an
EVITA score above zero indicating therapeutic advantage.
Conclusions: The strength of EVITA appears to lie in its speedy assessment of the potential therapeutic advantage
of a new drug for a given indication. At the same time, this approach draws attention to the typical deficits of
data used for drug approval. EVITA is not intended to replace classical health technology assessment reports but
rather serves as a screening tool in the sense of horizon scanning.
Background
Every year, numerous new drugs are introduced into the
pharmaceutical markets worldwide. In general, the ther-
apeutic efficiency of a drug is not satisfactorily defined
at the time of its approval by the health authorities. For
decades, a new pharmacological approach or a new
molecular structure, i.e. new chemical entity (NCE), per
se justified the claim that a compound represented a
pharmaceutical innovation. Today, however, a new com-
pound must exhibit a clinically relevant advantage over
the existing established therapy in order to be consid-
ered an innovation. Comprehensive health technology
assessments such as reports by the British National
Institute for Clinical Excellence (NICE) or the German
Institut für Qualität und Wirtschaftlichkeit im Gesund-
heitswesen (IQWiG) are, without doubt, the benchmark
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mon evaluation strategies, such as the “At h r o u g hD ”
classification used in Germany established by Fricke and
Klaus [1] are still based on the NCE principle and thus
simplify the result. More sophisticated evaluation strate-
gies like the one described recently by Caprino and
Russo [2] are well designed but appear to be too com-
plicated to be carried out by persons not specialized in
drug efficiency evaluation.
However, there is a clear lack of a transparent and
user friendly tool to answer the simple question of
whether a new compound offers an additional therapeu-
tic benefit over existing therapeutic strategies for a given
medical situation. This project has developed an algo-
rithm for the early evaluation of the risk-benefit ratio of
new drugs, EVITA (EValuation of pharmaceutical Inno-
vations with regard to Therapeutic Advantage). The
additional therapeutic benefit of a drug is assessed by
taking into account four considerations, a) therapeutic
aim, b) disease category, c) trial setting and, most
important, d) a score calculated by a benefit/risk consid-
eration. EVITA is intended to be used by physicians and
other professionals in the health sector, who are con-
cerned with innovations in pharmacotherapeutics.
EVITA is easy to use, however, basic knowledge in criti-
cal appraisal is a precondition.
Methods
Principle
Since therapeutic efficiency cannot be defined in general
terms but only in respect of a specific medical situation,
the EVITA algorithm can only be used to evaluate a
new compound for a given indication. EVITA attributes
positive or negative rating points to the drug in question
and its comparator in clinical trials by assessing both
therapeutic benefit and risk profile, i.e. rate and strength
of adverse effects attributed to the drug.
EVITA is not intended to generate an absolute score
value solely but a benefit/risk score annotated with specific
information on therapeutic aim, disease category and trial
setting. The therapeutic aim, distinguishing treatment from
prevention, has an impact on the EVITA score (see below)
(Table 1 + 2). Disease severity, however, graduated in four
categories from reversible and moderate discomfort to life-
threatening symptoms, has no effect on the EVITA score
even though it is essential when considering the benefit of
a drug as opposed to its risk profile. However, such apprai-
sal appears to be rather subjective, if not arbitrary. Thus,
the severity of the disease is categorized and documented
but is not a variable in the calculation (Table 1).
Trial settings
EVITA assessment initially defines the conditions which
must be met for the randomized controlled trials
(RCTs) to be included in the evaluation process. The
decision to include or exclude an RCT depends on the
one hand on the presence or absence of an established
therapy and on the other hand on the type of outcome
variables employed in these studies. As a minimum
requirement for an RCT to be taken into consideration
for EVITA evaluation, a Jadad Score of at least 3 has to
be met [3]. The respective decision pathway is outlined
in the form of a flowchart in Figure 1. As a result of the
decision-making tree, different “trial settings” of EVITA
can be defined.
Trial setting A represents clinical research which
addresses patient relevant outcomes including mortality,
reduced progression rate, event reduction, restoration or
preservation of functionality, control of symptoms and
quality of life. Within this A level, trial setting A1 applies
to testing the potential superiority of a new drug over
established therapy by one or more head-to-head RCTs.
The clinically relevant therapeutic benefit can also be
tested by comparison with placebo either directly, if there
is no established therapy, or administered on top of a
given established therapy, i.e. the add-on situation (trial
Table 1 Therapeutic Aim and Disease Category
prevention to reduce risk of disabling or imparing events
treatment to cure diseases, to substitute missing substances
indispensable to life, to modify or relieve symptoms
severity grading of the diseases:
I. acute life-threatening or severe chronic disease
II. rehabilitation
III. less severe acute or chronic disease
IV. application outside a treatment context
Therapeutic Aim and Disease Category according to disease severity
Table 2 Modifier
prevention
NNT ARR Modifier
<20 5-100% 2.0
20 - <50 <5% 1.75
50 - <100 <2% 1.5
100 - <175 <1% 1.25
175 - <300 <0.57% 1.0
300 - <500 <0.33% 0.75
500 - <1000 <0.2% 0.5
≥1000 <0.1% 0.25
treatment
NNT ARR Modifier
<3 >30% 2.0
3 - <10 10-30% 1.5
≥10 <10% 1.0
Assessment of the modifier for the efficiency score according to strength of
effect given in “number needed to treat” (NNT) or “absolute risk reduction”
(ARR).
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with respect to acceptable surrogate outcomes only, trial
setting B is attributed, with B1 for the head-to-head situa-
tion and B2 for the placebo comparison (including add-
on situations), as described for the A trial settings. In
situations with insufficient trials for a justified EVITA
calculation the trial setting is defined as N/A (EVITA cal-
culation not available).
Point scoring for efficiency, risk profile, and the EVITA
score
The compound of interest gains positive score points if
it is shown to be superior to the current established
therapy. In the absence of such established therapy,
superiority over placebo can be interpreted as therapeu-
tic benefit. Furthermore, the compound of interest
receives a positive rating if the investigational drug
demonstrates a more favorable risk profile than its
comparator.
Conversely, negative rating points are attributed to the
drug if the clinical trials result in inconclusive data, lack
of superiority or even proof of inferiority and/or a less
favorable risk profile than the comparator. Both the
benefit and the risk profile of the drug are evaluated on
the basis of RCTs.
The point scores for efficiency are modified by the
number of clinical trials, the trial setting encountered
and the therapeutic aim the agent is used for (Table 2
and 3). Superiority or inferiority proven by two or more
studies result in a higher positive or negative score than
proof from only one study (Table 3). Studies demon-
strating non-inferiority or equivalence of a new drug
compared with the given established therapy have to be
considered in a more differentiated way. In the case of
trials designed to demonstrate the superiority of an
investigational agent, a resultant positive score will be
reduced by tests showing non-inferiority or equivalence.
Conversely, in the case of inferiority trials, a resultant
negative score will be attenuated in favor of the investi-
gational agent by further studies showing non-inferiority
or equivalence. In respect of the superiority or inferior-
ity, two or more non-inferiority/equivalence trials will
have a higher numeric impact than only one (Table 3).
Point scores are multiplicated by two when evidence is
drawn from trials investigating patient-relevant out-
comes (trial setting A) than from trials investigating sur-
rogate outcomes only (trial setting B) (Table 3).
The efficiency score also takes into account the
strength of the therapeutic effect, the measure of which
is the number needed to treat (NNT). As can be seen
from Table 2, the modification of the efficiency score
due to the therapeutic strength is differentiated accord-
ing to the treatment goals. For preventive situations, the
N N T sm a yi n c r e a s et h eb e n e f i ts c o r e ,l e a v ei t
unchanged or even reduce it, which is reflected in the
requirement of prudently low NNTs to outweigh the
potentially negative consequences of long-term drug
therapy. In contrast, drugs for the therapy of acute dis-
orders with treatment aims such as healing and symp-
tom relief would, in general, have low NNTs. In this
Figure 1 Flowchart showing the decision tree leading to the EVITA trial settings.
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tive correction factor only for agents with a particularly
low NNT (Table 2).
The risk score of an investigational drug is based on
information about adverse effects and interactions with
other interventions. To ensure a balanced evaluation
and a justified comparison with the established therapy
or placebo, only data from controlled trials is included.
The adverse effects are scored on the basis of severity
and frequency (Table 4). EVITA considers the highest
occurrence of adverse effects (AE) from each of the
three severity groups Grades 4 and 5 (disabling AE or
life-threatening AE or death related to AE), Grade 3
(severe and undesirable AE) and Grades 1 and 2 (mild
AE or moderate AE) according to the Common Termi-
nology Criteria for Adverse Events (CTCAE Version 3.0,
2006) [4]. CTCAE grades are accepted criteria for the
evaluation of adverse effects in clinical studies, including
oncology trials. Frequency is evaluated according to the
guideline on Summary of Product Characteristics (SPC)
[5] in the following classes: rare/very rare (below 0.1%),
less common (0.1 through below 1.0%), common (1.0
through below 10.0%), and very common (10.0% and
above). It should be noted that very rare adverse effects
(< 0.01%) cannot usually be detected in clinical trials
because of limited subject numbers. Therefore, this fre-
quency is taken together with the frequency class rare.
The risk profile of an investigational drug cannot be
evaluated in isolation. It rather has to be compared with
that of the therapeutic alternative or the basal frequency
of adverse effects of the underlying disease. Therefore,
the score points for the risk profile are opposed to those
observed in the control groups in the clinical trials,
either the established therapy or placebo if applicable.
Thus, the eo ipso negative value of the risk score of the
investigational drug can be counterbalanced or even
reversed to give a positive value if the adverse effects of
the comparator dominate.
Interactions, mainly drug-drug-interactions, are a
potential source of risk which can emanate from a drug.
Since drug interactions are scarcely registered in clinical
trials, this information is taken from the SPC.
The final stage of EVITA is adding up the efficiency
and the risk score, both of which are evaluated in com-
parison to the established therapy, to obtain the EVITA
score. Values considerably above zero indicate a likely
potential that the new drug features a clinically relevant
improvement in treatment; values around zero indicate
an ambiguous state which might be clarified by further
clinical trials.
It is unlikely that a drug will be introduced into the
pharmaceutical market if its inferiority has been proven
by two or more RCTs investigating patient relevant out-
comes (-7.5) (Table 3) under established therapy or
Table 3 Efficiency Profile
RCTs showing evidence of number of RCT patient relevant outcome surrogate outcome
00 0
superiority 1 +5.0 +2.5
≥2 +7.5 +3.75
00 0
non-inferiority/equivalence
(in the presence of other RCT showing superiority)
1 -1.67 -0.83
≥2 -2.5 -1.25
non-inferiority/equivalence
(in the absence of other RCT)
any 0 0
00 0
non-inferiority/equivalence
(in the presence of other RCT showing inferiority)
1 +1.67 +0.83
≥2 +2.5 +1.25
00 0
inferiority 1 -5.0 -2.5
≥2 -7.5 -3.75
sum ...
modifier ...
efficiency score ...
Efficiency score according to number of RCTs and outcome variables investigated as well as modification by strength of effect as extracted by the modifier
assessment (Table 2).
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(Table 2), and with an unfavorable risk and interaction
profile in all severity groups (-8.0 and -2.0, respectively).
Therefore, the lowest calculable EVITA score of -25.0, is
not to be expected and should not arise. On the other
hand, the maximum calculable EVITA score of +25.0
also appears unlikely since it would result from proof of
superiority over the comparator in a treatment situation
in at least two RCTs investigating patient relevant out-
comes (+7.5) with low NNT (modifying factor 2.0) and
a complete absence of adverse effects and interactions,
while the comparator featured an unfavorable risk and
interaction profile. Scores in the range of -5 to +10 are
therefore to be expected as the typical EVITA result. It
should be noted that EVITA may demonstrate an addi-
tional therapeutic benefit of a new compound despite a
lack of superior efficiency because of a better risk and
interaction profile.
Since exact score values might suggest a more precise
evaluation than EVITA can provide, the EVITA score is
displayed as a color-coded bar graph, with green (positive
values) indicating a compound that is likely to be innova-
tive, yellow (values around zero) indicating an unclear
result at the time and red (negative values) indicating an
unlikely probability that the compound will offer an addi-
tional therapeutic benefit (Figures 2a-d). Further, a traf-
fic-type yield sign incorporating a question mark is
attributed for situations in which available data are
unsuitable for an EVITA calculation indicating N/A trial
settings (Figure 2e).
Transparency is a major concern of the EVITA pro-
ject. To accomplish this, EVITA evaluation results are
presented online http://www.evita-report.de together
with the complete list of the source RCTs and the rea-
sons for excluding any particular RCT from the evalua-
t i o n .T h i sa l s oa l l o w sf o rr a p i dr e v i s i o ni nr e s p o n s et o
justified criticism and simplifies the inclusion of new
data e.g. from a new RCT publication.
Results
Lenalidomide for the treatment of refractory or relapsing
multiple myeloma
Lenalidomide (Anatomic Therapeutic Chemical (ATC)
Classification: L04AX04), a structural analogue to thali-
domide, was introduced in 2007 (Germany), in combina-
tion with dexamethasone for the treatment of refractory
or relapsing multiple myeloma (International Classifica-
tion of Diseases Version 10 (ICD-10): C90) after at least
Table 4 Risk-Profile
severity grading frequency therapy investigated therapeutic standard
adverse events (AE)
grades 5 + 4 ≥10% -4.0 -4.0
(death related to AE or life-threatening AE or disabling AE) ≥1% -3.0 -3.0
≥0.1% -2.0 -2.0
<0.1% -1.0 -1.0
0 00
grade 3 ≥10% -2.5 -2.5
(severe and undesirable AE) ≥1% -2.0 -2.0
≥0.1% -1.0 -1.0
<0.1% 00
0 00
grades 2 + 1 ≥10% -1.5 -1.5
(moderate AE or mild AE) ≥1% -1.0 -1.0
≥0.1% -0.5 -0.5
<0.1% 00
0 00
Interactions
frequent or serious clinical consequence -2.0 -2.0
occasional or may have clinical consequence -1.5 -1.5
dose change -1.0 -1.0
unlikely/probably or no clinical consequence 00
no information available -1.0 -1.0
sum ... ...
risk score ...
Risk Score Assessment. The severity grading is carried out according to the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) [4], the
frequency according to the Guideline on Summary of Product Characteristics (SPC) [5]
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Püntmann et al. BMC Clinical Pharmacology 2010, 10:5
http://www.biomedcentral.com/1472-6904/10/5
Page 6 of 11one completed previous therapy [6,7]. Numerous thera-
peutic approaches are currently considered established
treatment alternatives for this situation: high-dose
dexamethasone, anthracycline ± vincristine-containing
chemotherapeutic schemes, bendamustine, cyclopho-
sphamide, bortezomib, or a second autologous stem cell
transplantation can be taken as established therapy for
this situation [8-11]. Without doubt, the therapeutic aim
is “treatment” of a life-threatening disease indicating dis-
ease category I.
Two studies were found which met the EVITA
requirements [12,13]. However, since both trials meticu-
lously used the identical study protocol, were performed
in the identical number and profile of patients and dur-
ing the same time period, they have to be considered as
one clinical trial. All patients received high dose dexa-
methasone and were randomly assigned to either addi-
tional lenalidomide or placebo.
Outcome was primarily measured using time to
progression (TTP). Strictly speaking, this variable is a
surrogate outcome. However, since, the overall survival
(OS), measured as a secondary outcome, showed a clear
tendency in favor of the study drug in this trial, TTP
was accepted as a clinically relevant outcome. Thus,
EVITA trial setting A2 applies, because lenalidomide
was compared with placebo in an add-on situation with
an established therapy using patient relevant outcomes
(Figure 1). In the light of further established therapeutic
alternatives the conclusion must be restricted to patients
for whom dexamethasone appeared as the only
therapeutic option.
The statistically significant outcome advantage demon-
strated in one study attributes +5.0 points to lenalido-
mide (Table 3). As no NNT calculation is possible for
the variable TTP, the higher proportion of patients, by
over 38%, with an overall response was used instead,
a s s u m i n gap o s i t i v ec o r r e l a t i o nb e t w e e nt h e s ev a r i a b l e s .
The NNT of 2.6 in 1.5 years (indicating 4 per year)
results in a modifier factor of 1.5 (Table 2). The result-
ing efficiency score is +7.5.
The risk profile was calculated on the basis of obser-
vations of the adverse effect in the clinical trials used
for the efficiency evaluation. There was a very similar
frequency of adverse effects in the two treatment
groups. Only grade 3 severity group adverse effects
occurred slightly less frequently in the placebo group; in
addition, there is a clinically relevant drug interaction
risk, while for placebo interaction potential must be
considered zero. The resultant risk score for lenalido-
mide is -1.5 (Table 4).
Taking efficiency and risk score together, gives an
EVITA score of +6.0, indicating a rather likely chance
that lenalidomide represents a patient relevant
innovative drug for the specific subgroup of patients
investigated in the trials cited (Figure 2a).
Pioglitazone in the treatment of diabetes mellitus
Pioglitazone (ATC: A10BG03) is a thiazolidindione in
the treatment of diabetes mellitus type 2 (DM2) (ICD-
10: E10-E14) [14]. The evaluation was carried out twice,
once based on the knowledge available in 2001, i.e.
shortly after drug approval, and the other based on the
knowledge of 2005, i.e. after publication of the PROac-
tive study (PROspective pioglitAzone Clinical Trial In
macroVascular Events) [15], a large outcome trial in dia-
betic patients.
Oral antidiabetics seek to protect the patient from
macro- and microvascular sequelae, thus the therapeutic
aim is “prevention”. There are widely accepted estab-
lished oral antidiabetic therapies, mainly using metfor-
min and sulphonylurea compounds. In the pivotal
studies [16,17], pioglitazone was tested in an add-on
trial setting, metformin or sulphonylureas being
employed as basal therapy. The outcome variable was
glycosylated hemoglobin A1c (HbA1c), i.e. a surrogate
variable. In view of the fact that the therapeutic effi-
ciency of alternative oral antidiabetics, mainly metfor-
min, was assured by clinical trials using patient relevant
outcomes, a trial using surrogates only should no longer
be accepted according to the EVITA evaluation strategy.
However, since metformin was given as a basal drug in
both groups, the therapeutic benefit of other antidiabetics
on top of metformin is not satisfactorily ensured, and
lowering blood glucose in diabetic patients is widely
accepted as a necessary therapeutic goal, the trials using
HbA1c as primary efficacy outcome were accepted.
Hence, EVITA trial setting B2 applies (Figure 1).
For HbA1c, pioglitazone showed significant benefit
over placebo in two trials, resulting in an efficiency
score of +3.75 points, rounded to +4.0 (Table 3). The
NNT for such a benefit cannot be calculated from this
outcome. Therefore, since no other outcomes closely
associated with the primary outcome were reported in
this study the efficiency score was not modified further.
The risk profile evaluation taken from the two trials
showed an occurrence of less than 10% of both severe
(-2.0 points) and mild to moderate (-1.0 points) adverse
effects, but this applied to both the pioglitazone and the
placebo treatment arm, so that the net risk for pioglita-
zone resulted in zero. According to the SPC, severe
interactions with gemfibrozil and rifampicin may require
dose changes of pioglitazone for which one negative
score point is given, while for the comparator (placebo)
a zero interaction potential is assumed (Table 4). The
efficiency point score is +4.0 and the risk score -1.0,
resulting in an EVITA score of +3.0 points which
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pharmacological candidate (Figure 2b).
Five years after approval, the results of the PROactive
study were published [15]. In this trial, the effects of
pioglitazone on the macrovascular outcome of over
5,000 DM2 patients treated with pioglitazone or pla-
cebo, both on top of established therapy, were investi-
gated. The primary outcome - a composite of seven
clinical events - is considered to be patient relevant so
that EVITA trial setting A2 applies, i.e. a comparison of
the patient relevant outcomes of an investigational drug
with those of a placebo in an add-on situation (Figure
1). This trial failed to show the superiority of pioglita-
zone over placebo. According to the EVITA strategy,
RCTs with patient relevant outcomes rule out trials with
surrogate variables. Thus, unlike the earlier evaluation,
the efficiency score decreases to zero (Table 3). Even if
the individual risk profiles, as extracted from the Dor-
mandy study, were changed from -7.5 points to -6.5
points, the reconciliation of both risk profiles would
remain the same (-1.0 points) (Table 4) and the EVITA
score would become negative (-1.0 points) (Figure 2c).
According to the EVITA philosophy, point scores
around zero are considered inconclusive for the inter-
pretation of the innovative value of a new pharmacologi-
cal candidate. Thus the aforementioned promise of an
additional value is negated.
It should be noted that in the same publication [15]
the authors communicated an additional outcome vari-
able comprising only three of the seven original out-
come components. This new outcome variable showed a
statistically significant superiority of pioglitazone over
placebo. However, since this variable was not mentioned
in the original protocol [18], it cannot be considered
predefined and thus cannot be included in the EVITA
evaluation.
Bupropion in the treatment of episodes of major
depression
Bupropion (ATC: N06AX12, N07BA02) is a reuptake
inhibitor of norepinephrine, dopamine, and, to a lesser
degree, serotonine; it is also a nicotinic receptor antago-
nist. Originally marketed in the United States in 1984,
bupropion was not introduced as an antidepressant in
Germany until 2007 [19,20]. Major depression (ICD-10:
F32-F39) is a severe if not life-threatening disease due
to its elevated risk of suicide. Therefore category I
applies. Although prevention is one aspect of antide-
pressive therapy, its main focus in the majority of
patients is on the reduction of disease burden, thus
defining the therapeutic aim as “treatment”.
Bupropion has been on the pharmaceutical market for
over two decades, so there is a plethora of clinical trial
information. The majority of the older studies do not,
however, meet the quality requirements of modern trial
methodology such as conformity with Good Clinical
Practice (GCP) or they focused on side effects such as
disorders in sexual function as primary outcome. There-
fore, they are unsuitable for EVITA evaluation of
the therapeutic efficiency of bupropion. Some of the
recently published studies [21-23] used placebo as the
comparator. This cannot be accepted in indications
where established therapies exist. Thus, only a minority
of trials met the requirements for EVITA evaluation.
To fully assess all studies of antidepressant efficiency
with an acceptable comparator, not only the trials pub-
lished in peer-reviewed scientific journals were
inspected, but also those published as abstracts on the
company website, “GlaxoSmithKline (GSK) Clinical
Trial Register”. Finally, three trials were identified as sui-
table for EVITA evaluation. In a six-week study of 100
depressed patients [24], bupropion did not show super-
iority with respect to the Hamilton-scale (HAMD-17)
over paroxetin, an antidepressant acceptable as estab-
lished therapy. In two three-arm studies, only available
online in the GSK Clinical Trial Register [25,26], bupro-
pion was compared to placebo and venlafaxin using the
“Montgomery-Asberg Depression Rating Scale"(MADRS)
measuring changes after 8 or 10 weeks. The two studies
showed divergent results. In one [25], while patients
treated with bupropion showed a larger MADRS-score
reduction than those under placebo, there was no differ-
ence in comparison to venlafaxine. In the other trial
[26] bupropion induced similar MADRS-score reduc-
tions compared to placebo, albeit a smaller one when
compared to venlafaxin.
Since each of the three trials represents a direct com-
parison with an established therapy and since scale-
scores which quantify the severity of a disease generally
have to be considered as surrogate, EVITA trial setting
B1 applies (Figure 1). Therapeutic superiority over estab-
lished therapy was not seen in any trial (0); however,
inferiority in one study (-2.5) and equivalence in two
studies (+1.25), resulted in a efficiency score of -1.25
which does not need to be adjusted for treatment
strength (Table 3).
Due to the lack of complete publication of the three
studies taken for the efficiency evaluation, there was
insufficient information on the adverse effects profile of
bupropion. Therefore, the respective SPC information
was used to evaluate the risk profile. For comparison,
the risk profile informationi nt h eS P C so fv e n l a f a x i n
and paroxetin were considered. Since all compounds
have been on the market for many years now, this pro-
cedure appeared to be justified. Although not all adverse
effects (AE) were attributable to all the compounds,
bupropion and its comparators paroxetin and venlafaxin,
featured similar AE frequencies in all severity groups.
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mild AE or moderate AE (Grades 1 and 2) very com-
monly, severe and undesirable AE (Grade 3) very com-
monly, and disabling AE or life-threatening AE or death
related to AE (Grades 4 and 5) less commonly. Drug
interactions occur occasionally and can also lead to clin-
ical consequences during treatment with all of the three
compounds. Thus, a point score of (-1.5) + (-2.5) +
(-2.0) + (-1.5) = (-7.5) was calculated for the risk profiles
of both bupropion and its comparators (venlafaxin
and paroxetin), resulting in a risk score of zero for
bupropion (Table 4).
The EVITA score for bupropion, obtained by adding
up the -1.25 points for efficiency and the zero value for
the relative risk profile was -1.25, indicating that
an additional therapeutic benefit for bupropion in the
treatment of major depression can hardly be expected
(Figure 2d).
Zoledronic acid (5 mg annually) for the treatment of
postmenopausal osteoporosis (PMO)
Zoledronic acid (ATC: M05BA08) is a nitrogen-contain-
ing bisphosphonate which inhibits osteoclast-mediated
bone resorption [27,28]. In Europe, intravenous zoledro-
nic acid (4 mg administered every 3 to 4 weeks) was
approved in 2001 for the prevention of skeletal compli-
cations in patients with bone metastases and for the
treatment of tumor-induced hypercalcaemia [29]. It was
introduced in 2005 as an annual intravenous formula-
tion (5 mg/y) for the treatment of Morbus Paget [30]. In
2007, it was approved in the same dosage for the treat-
ment of patients with PMO on high risk of fracture
[31,32] (ICD-10: C80-C81), for which many other intra-
venous as well as oral bisphosphonates have been
granted market authorization. PMO is a severe disease
due to its elevated risk fractures, which if affecting the
hip might be life-threatening. Therefore “treatment” and
“category 1” apply for therapeutic aim and disease sever-
ity, respectively. From evidence-based perception,
bisphosphonates, particularly alendronic and risedronic
acid, raloxifene and estrogenes, are considered estab-
lished therapies in the treatment of osteoporosis, as they
have been proven to reduce the occurrence of clinically
relevant bone fractures.
Two studies of zoledronic acid (5 mg once per year)
treatment of PMO have been published so far. A dose-
efficiency trial [33] investigated the influence on bone
mineral density, a surrogate outcome. The pivotal trial
HORIZON (Health Outcomes and Reduced Incidence
with Zoledronic Acid Once Yearly) [34] investigated two
primary efficiency outcomes, one of surrogate quality
(risk reduction of morphometric vertebral fracture) and
one of patient relevant quality (risk reduction of hip
fracture). However, both trials were conducted in
comparison with placebo. Against the background of
existing established therapies, these studies did not fulfill
the requirements for EVITA evaluation. As a conse-
quence, zoledronic acid (5 mg annually) in the indica-
tion PMO had to be rated N/A (Figure 2e).
Discussion
The main innovation of EVITA is to challenge the value
of innovation per se. Previously, a new drug develop-
ment was considered innovative when it featured a new
chemical entity or had an effect on new pharmacological
targets such as receptors, enzymes and signaling or tran-
scriptional proteins. There is an abundance of drugs
which after approval, in spite of positive initial expecta-
tions, have failed to demonstrate a clinically relevant
benefit in controlled study situations or under everyday
conditions. Well-known examples are flecainide [35],
troglitazone [36], estrogens [37,38]) and ximelagatran
[39]. Against this background, the mission of the EVITA
evaluation tool is to focus strictly on the therapeutic
benefit of the investigational drug. More importantly,
EVITA compares the drug with other therapeutic
approaches which are accepted as established therapy.
Thus, EVITA does not evaluate the efficacy or efficiency
of a new drug per se, but rather the potential superiority
over a given established therapy. It should be noted that
innovative value is also attributed by EVITA to a new
pharmaceutical product, if it results - with similar effi-
ciency - from a more favorable profile of adverse effects.
EVITA comparisons of therapeutic principles are valid
only for one and the same specific indication.
In the interests of a well-balanced comparison, adverse
effect data is taken mainly from the same clinical studies
as the data for the comparison of the investigational
drug with the established therapy. Only if no satisfactory
data is available, or if the compound has been on the
market for a long time, is the adverse effect information
for the investigational drug or the comparator extracted
from the SPC.
An EVITA assessment, including all the elements
from “therapeutic aim” to “EVITA score”, is the evalua-
tion of the additional therapeutic value of a new drug in
a given indication. Attribution of the “N/A” assessment
means that an EVITA calculation was not available due
to insufficient data. This is, without any doubt, an
assessment result. By gaining an N/A assessment, even
more serious concerns are raised against a new drug
regarding its potential contribution to the therapeutic
choices in this indication. Moreover, the N/A result can
be considered as a criticism passed on the methods to
develop drugs and push them into the markets.
As is true for any health technology evaluation proce-
dure, EVITA is characterized by obvious strengths but
also weaknesses. A weakness might be that the NNTs
Püntmann et al. BMC Clinical Pharmacology 2010, 10:5
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available from all the clinical trials, which is particularly
true of studies using surrogate scale-scores as outcomes
and of older compounds. Since EVITA will be further
developed and validated for drugs which are immedi-
ately pre- or post-approval, the lack of NNT calculation
will, however, be a rare rather than a frequent problem.
In addition, EVITA, in the present version, does not
allow weighting studies for methodological quality. This
will hamper its applicability when numerous and metho-
dologically different studies have already been per-
formed. However, EVITA was developed for the
assessment of new, recently approved compounds, i.e.
when data from only a few clinical trials are available.
One of the strengths of EVITA, on the other hand, is its
transparency. Once established, EVITA evaluations will
be published on the internet http://www.evita-report.de
together with all clinical data upon which they are
based. In addition, the evaluation per se is transparent,
since all details such as positive and negative point
scores and correction factors are clearly stated. The
most important strength of EVITA is probably the fact
that it can be easily and quickly adapted to the results
of new clinical trials or even to a new interpretation of
such data. This is especially important, since only a few
clinical trials are available at the time of a drug’s market
entrance and its clinical relevance can often only be
confirmed or denied by integrating new evidence into
the evaluation process.
Conclusions
EVITA has not been developed to replace established
tools of comprehensive health technology assessment,
since important methodological characteristics such as
meta-analytical calculations are not included. It is rather
intended to answer, in the sense of horizon scanning, the
simple question of what a new drug will add to the thera-
peutic strategies already available for a given disease. The
strict evaluation algorithm should stimulate, in addition,
the discussion on the innovative value of new pharmaco-
logical compounds. In the next step of the project, the
point scoring of both benefit and risk will be tested on
larger numbers of newer and older pharmaceuticals both
immediately and years after their market authorization to
test the “forecast” value of EVITA. EVITA results will be
presented on the internet to enhance professional debate
about medical progress in pharmacotherapy.
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